Stryker (SYK)
(Delayed Data from NYSE)
$351.22 USD
-0.39 (-0.11%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $351.29 +0.07 (0.02%) 7:12 PM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
Company Summary
Headquartered in Kalamazoo, MI, Stryker Corporation is one of the world’s largest medical device companies operating in the global orthopedic market. The company has three business segments: Orthopaedics, MedSurg, and Neurotechnology & Spine.
Orthopaedic products primarily include implants used in hip and knee joint replacements and trauma and extremities surgeries.
MedSurg products consists of surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical); and reprocessed and remanufactured medical devices (Sustainability) as well as other ...
Company Summary
Headquartered in Kalamazoo, MI, Stryker Corporation is one of the world’s largest medical device companies operating in the global orthopedic market. The company has three business segments: Orthopaedics, MedSurg, and Neurotechnology & Spine.
Orthopaedic products primarily include implants used in hip and knee joint replacements and trauma and extremities surgeries.
MedSurg products consists of surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical); and reprocessed and remanufactured medical devices (Sustainability) as well as other medical device products used in a variety of medical specialties.
Neurotechnology & Spine division includes both neurosurgical and neurovascular devices. These includes products used for minimally invasive endovascular techniques; traditional brain and open skull base surgical procedures; orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke.
Spinal implant product offering includes cervical, thoracolumbar and interbody systems used in spinal injury, deformity and degenerative therapies.
It is important to note here that effective from Dec 31, 2021, Stryker has updated its reportable business segments to align to its new internal reporting structure.
2023 at a Glance
Stryker’s full-year revenues totaled $20.5 billion, up 11.1% from the previous year. Adjusted earnings per share of $10.60 increased 13.5% from the previous year.
General Information
Stryker Corporation
1941 Stryker Way
Portage, MI 49002
Phone: 269-385-2600
Fax: 269-385-1062
Web: http://www.strykercorp.com
Email: jason.beach@stryker.com
Industry | Medical - Products |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 9/30/2024 |
Earnings Date | 10/29/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 2.78 |
Current Year EPS Consensus Estimate | 12.00 |
Estimated Long-Term EPS Growth Rate | 10.80 |
Earnings Date | 10/29/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 351.61 |
52 Week High | 374.63 |
52 Week Low | 249.98 |
Beta | 0.91 |
20 Day Moving Average | 1,070,449.75 |
Target Price Consensus | 381.00 |
4 Week | -1.78 |
12 Week | 4.00 |
YTD | 17.42 |
4 Week | -5.17 |
12 Week | 1.89 |
YTD | -1.74 |
Shares Outstanding (millions) | 381.08 |
Market Capitalization (millions) | 133,989.89 |
Short Ratio | NA |
Last Split Date | 5/17/2004 |
Dividend Yield | 0.91% |
Annual Dividend | $3.20 |
Payout Ratio | 0.28 |
Change in Payout Ratio | -0.02 |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 29.31 |
Trailing 12 Months | 31.31 |
PEG Ratio | 2.72 |
vs. Previous Year | 10.63% |
vs. Previous Quarter | 12.40% |
vs. Previous Year | 8.53% |
vs. Previous Quarter | 3.41% |
Price/Book | 6.78 |
Price/Cash Flow | 26.22 |
Price / Sales | 6.26 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 22.89 |
3/31/24 | 23.05 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 11.03 |
3/31/24 | 10.88 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 1.68 |
3/31/24 | 1.71 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 0.95 |
3/31/24 | 0.99 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 20.18 |
3/31/24 | 20.07 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 16.12 |
3/31/24 | 16.03 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 18.78 |
3/31/24 | 18.68 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 51.86 |
3/31/24 | 50.33 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 1.57 |
3/31/24 | 1.57 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 0.51 |
3/31/24 | 0.56 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 33.88 |
3/31/24 | 36.05 |